Pharma Mar SA
OTC:PHMMF
Intrinsic Value
Pharma Mar SA is a biopharmaceutical holding company, which engages in research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. [ Read More ]
The intrinsic value of one PHMMF stock under the Base Case scenario is 39.03 USD. Compared to the current market price of 31.15 USD, Pharma Mar SA is Undervalued by 20%.
Valuation Backtest
Pharma Mar SA
Run backtest to discover the historical profit from buying and selling PHMMF stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Pharma Mar SA
Current Assets | 252.6m |
Cash & Short-Term Investments | 162.6m |
Receivables | 27.6m |
Other Current Assets | 62.5m |
Non-Current Assets | 87.9m |
Long-Term Investments | 6.9m |
PP&E | 47.6m |
Intangibles | 1.9m |
Other Non-Current Assets | 31.5m |
Current Liabilities | 95.9m |
Accounts Payable | 31.3m |
Other Current Liabilities | 64.6m |
Non-Current Liabilities | 51.2m |
Long-Term Debt | 28.9m |
Other Non-Current Liabilities | 22.3m |
Earnings Waterfall
Pharma Mar SA
Revenue
|
158.2m
EUR
|
Cost of Revenue
|
-9.6m
EUR
|
Gross Profit
|
148.5m
EUR
|
Operating Expenses
|
-152.6m
EUR
|
Operating Income
|
-4.1m
EUR
|
Other Expenses
|
5.2m
EUR
|
Net Income
|
1.1m
EUR
|
Free Cash Flow Analysis
Pharma Mar SA
PHMMF Profitability Score
Profitability Due Diligence
Pharma Mar SA's profitability score is 64/100. The higher the profitability score, the more profitable the company is.
Score
Pharma Mar SA's profitability score is 64/100. The higher the profitability score, the more profitable the company is.
PHMMF Solvency Score
Solvency Due Diligence
Pharma Mar SA's solvency score is 63/100. The higher the solvency score, the more solvent the company is.
Score
Pharma Mar SA's solvency score is 63/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PHMMF Price Targets Summary
Pharma Mar SA
According to Wall Street analysts, the average 1-year price target for PHMMF is 52.05 USD with a low forecast of 29.47 USD and a high forecast of 72.45 USD.
Shareholder Return
PHM Price
Pharma Mar SA
Average Annual Return | 37.62% |
Standard Deviation of Annual Returns | 52.65% |
Max Drawdown | -80% |
Market Capitalization | 557.4m EUR |
Shares Outstanding | 18 176 100 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Pharma Mar SA is a biopharmaceutical holding company, which engages in research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. The company is headquartered in Colmenar Viejo, Madrid and currently employs 477 full-time employees. The company went IPO on 2015-11-02. The Company, through its subsidiaries, operates three business segments: Oncology, Diagnostics and RNA interference. The Oncology segment encompasses research, develop and market anti-tumor drugs. The Diagnostics segment includes the development and marketing of diagnostic kits. The RNA interference segment consist of the development of drugs with therapeutic activity based on reducing or silencing gene expression. The Company’s product portfolio includes Yondelis and ZEPZELCA. Yondelis (trabectedin) is indicated for the treatment of advanced soft tissue sarcoma, as well as for the treatment of relapsed platinum-sensitive ovarian cancer. ZEPZELCA (lurbinectedin) is indicated for the treatment of metastatic small cell lung cancer (SCLC) with disease progression. The firm is active globally.
Contact
IPO
Employees
Officers
The intrinsic value of one PHMMF stock under the Base Case scenario is 39.03 USD.
Compared to the current market price of 31.15 USD, Pharma Mar SA is Undervalued by 20%.